XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2024
Concentration Risk And Geographic Information [Abstract]  
Schedule of Disaggregation of Total Net Product Revenues by Product
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
March 31,
20242023
VIMIZIM$192,520 $189,192 
VOXZOGO152,889 87,836 
NAGLAZYME105,629 123,021 
PALYNZIQ75,709 62,352 
BRINEURA39,047 39,144 
KUVAN35,910 50,478 
ALDURAZYME35,262 34,403 
ROCTAVIAN849 — 
Total net product revenues637,815 586,426 
Royalty and other revenues11,018 9,989 
Total revenues$648,833 $596,415 
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
March 31,
20242023
United States$192,999 $166,761 
Europe195,748 160,692 
Latin America78,594 67,748 
Middle East57,075 91,642 
Rest of world78,137 65,180 
Total net product revenues marketed by the Company602,553 552,023 
ALDURAZYME net product revenues marketed by Sanofi35,262 34,403 
Total net product revenues$637,815 $586,426 
Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
Three Months Ended
March 31,
20242023
Customer A14 %14 %
Customer B11 %10 %
Total25 %24 %